Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Brian J. Ball; Christopher A. Famulare; Eytan M. Stein; Martin S. Tallman; Andriy Derkach; Mikhail Roshal; Saar I. Gill; Benjamin M. Manning; Jamie Koprivnikar; James McCloskey; Rebecca Testi; Thomas Prebet; Najla H.Al Ali; Eric Padron; David A. Sallman; Rami S. Komrokji; Aaron D. Goldberg

doi:10.1182/bloodadvances.2020001482

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Brian J. Ball, Christopher A. Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar I. Gill, Benjamin M. Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prebet, Najla H.Al Ali, Eric Padron, David A. Sallman, Rami S. Komrokji, Aaron D. Goldberg

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Original language	English (US)
Pages (from-to)	2866-2870
Number of pages	5
Journal	Blood Advances
Volume	4
Issue number	13
DOIs	https://doi.org/10.1182/bloodadvances.2020001482
State	Published - Jul 14 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2020001482

Cite this

Ball, B. J., Famulare, C. A., Stein, E. M., Tallman, M. S., Derkach, A., Roshal, M., Gill, S. I., Manning, B. M., Koprivnikar, J., McCloskey, J., Testi, R., Prebet, T., Ali, N. H. A., Padron, E., Sallman, D. A., Komrokji, R. S., & Goldberg, A. D. (2020). Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Advances, 4(13), 2866-2870. https://doi.org/10.1182/bloodadvances.2020001482

@article{11e04c4aa263481e868d046fdc89c959,

title = "Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure",

author = "Ball, {Brian J.} and Famulare, {Christopher A.} and Stein, {Eytan M.} and Tallman, {Martin S.} and Andriy Derkach and Mikhail Roshal and Gill, {Saar I.} and Manning, {Benjamin M.} and Jamie Koprivnikar and James McCloskey and Rebecca Testi and Thomas Prebet and Ali, {Najla H.Al} and Eric Padron and Sallman, {David A.} and Komrokji, {Rami S.} and Goldberg, {Aaron D.}",

note = "Funding Information: received research funding from Novartis, Tmunity Therapeutics, and Carisma Therapeutics; served on advisory panel/consultant for Amphivena, Aro, Intellia, and Sensei Bio; and has equity ownership in Carisma Therapeutics. J.K. served on speakers bureau for Amgen, AbbVie, and Novartis and received honoraria from Pfizer. T.P. received research funding from Jazz, BMS, and Agios and honoraria from Genentech, Agios, Pfizer, and Novartis. E.P. received research funding from Incyte, Kura Oncology, Celgene. D.A.S. served on speaker{\textquoteright}s bureaus for Novartis, AbbVie, Incyte, and Celgene; received research funding from Celgene and Jazz; and served on a board of directors or advisory committee for Celyad. R.S.K. served as a consultant for Pfizer, DSI, Incyte, Agios, Funding Information: Conflict-of-interest disclosure: E.M.S. served on the board of directors or advisory committee for Agios, Astellas Pharma US, Celgene, Daiichi Sankyo, Genentech, Novartis, PTC Therapeutics, Syros, Bioline, and Biotheryx and served as a consultant for Agios. M.S.T. receives research funding from ADC Therapeutics, Biosight, AbbVie, Cellerant, Orsenix, Glycomimetics, Rafael, and Amgen; served on the advisory board for Rigel, Nohla, BioLineRx, Oncolyze, D Fly Pharma, Daiichi-Sankyo, KAHR, AbbVie, Orsenix, Tetraphase, Jazz, and Roche; and receives royalties from UpToDate. S.I.G.",

year = "2020",

month = jul,

day = "14",

doi = "10.1182/bloodadvances.2020001482",

language = "English (US)",

volume = "4",

pages = "2866--2870",

journal = "Blood advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "13",

}

Ball, BJ, Famulare, CA, Stein, EM, Tallman, MS, Derkach, A, Roshal, M, Gill, SI, Manning, BM, Koprivnikar, J, McCloskey, J, Testi, R, Prebet, T, Ali, NHA, Padron, E, Sallman, DA, Komrokji, RS & Goldberg, AD 2020, 'Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure', Blood Advances, vol. 4, no. 13, pp. 2866-2870. https://doi.org/10.1182/bloodadvances.2020001482

TY - JOUR

T1 - Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

AU - Ball, Brian J.

AU - Famulare, Christopher A.

AU - Stein, Eytan M.

AU - Tallman, Martin S.

AU - Derkach, Andriy

AU - Roshal, Mikhail

AU - Gill, Saar I.

AU - Manning, Benjamin M.

AU - Koprivnikar, Jamie

AU - McCloskey, James

AU - Testi, Rebecca

AU - Prebet, Thomas

AU - Ali, Najla H.Al

AU - Padron, Eric

AU - Sallman, David A.

AU - Komrokji, Rami S.

AU - Goldberg, Aaron D.

N1 - Funding Information: received research funding from Novartis, Tmunity Therapeutics, and Carisma Therapeutics; served on advisory panel/consultant for Amphivena, Aro, Intellia, and Sensei Bio; and has equity ownership in Carisma Therapeutics. J.K. served on speakers bureau for Amgen, AbbVie, and Novartis and received honoraria from Pfizer. T.P. received research funding from Jazz, BMS, and Agios and honoraria from Genentech, Agios, Pfizer, and Novartis. E.P. received research funding from Incyte, Kura Oncology, Celgene. D.A.S. served on speaker’s bureaus for Novartis, AbbVie, Incyte, and Celgene; received research funding from Celgene and Jazz; and served on a board of directors or advisory committee for Celyad. R.S.K. served as a consultant for Pfizer, DSI, Incyte, Agios, Funding Information: Conflict-of-interest disclosure: E.M.S. served on the board of directors or advisory committee for Agios, Astellas Pharma US, Celgene, Daiichi Sankyo, Genentech, Novartis, PTC Therapeutics, Syros, Bioline, and Biotheryx and served as a consultant for Agios. M.S.T. receives research funding from ADC Therapeutics, Biosight, AbbVie, Cellerant, Orsenix, Glycomimetics, Rafael, and Amgen; served on the advisory board for Rigel, Nohla, BioLineRx, Oncolyze, D Fly Pharma, Daiichi-Sankyo, KAHR, AbbVie, Orsenix, Tetraphase, Jazz, and Roche; and receives royalties from UpToDate. S.I.G.

PY - 2020/7/14

Y1 - 2020/7/14

UR - http://www.scopus.com/inward/record.url?scp=85088699290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088699290&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2020001482

DO - 10.1182/bloodadvances.2020001482

M3 - Article

C2 - 32589727

AN - SCOPUS:85088699290

VL - 4

SP - 2866

EP - 2870

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 13

ER -

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this